Core Viewpoint - Bicara Therapeutics Inc. has announced a public offering of 7,175,000 shares at $16.00 per share, aiming to raise approximately $150 million to support its clinical and commercial initiatives for ficerafusp alfa, a bifunctional therapy for solid tumors [1][2]. Group 1: Offering Details - The public offering includes pre-funded warrants for 2,200,000 shares at a price of $15.9999 each, with gross proceeds expected to be around $150 million before expenses [1]. - The offering is set to close on or about February 26, 2026, pending customary closing conditions [1]. - Underwriters have a 30-day option to purchase up to 1,406,250 additional shares at the public offering price [1]. Group 2: Use of Proceeds - Net proceeds will be used to enhance medical and commercial infrastructure for a planned regulatory filing and launch of ficerafusp alfa in the U.S. [2]. - Funds will also support the development of ficerafusp alfa in first-line recurrent/metastatic HPV-negative head and neck squamous cell carcinoma, including a less frequent dosing schedule [2]. - Additional uses include covering manufacturing costs for ongoing drug development and early signal-finding for future indication expansion [2]. Group 3: Company Overview - Bicara Therapeutics is focused on developing bifunctional therapies for solid tumors, with its lead program, ficerafusp alfa, designed to penetrate tumors by overcoming barriers in the tumor microenvironment [6]. - Ficerafusp alfa combines an EGFR-directed monoclonal antibody with a domain that binds to TGF-β, aiming to reverse the fibrotic and immune-excluded tumor microenvironment [6]. - The therapy is being developed for head and neck squamous cell carcinoma and other solid tumor types, addressing significant unmet medical needs [6].
Bicara Therapeutics Announces Pricing of $150 Million Public Offering of Common Stock and Pre-Funded Warrants